SEC, FDA Ink Data-Sharing Pact Targeting Life Sciences
A new memorandum of understanding facilitates SEC access to FDA records, signaling heightened scrutiny of issuer disclosures and insider trading in the pharma and biotech sectors.
The US Securities and Exchange Commission (SEC) and Food and Drug Administration (FDA) signed a Memorandum of Understanding on August 31, 2026, creating a formal framework for sharing information to support each agency's regulatory and enforcement responsibilities. While not creating new substantive law, the pact gives the SEC a more direct and standardized process for obtaining non-public information from the FDA, making it easier to investigate whether a company's public statements about clinical trial results, product approvals, or other FDA interactions are false or misleading.
Sophisticated counsel should care because this signals a heightened enforcement focus on the life sciences industry. The SEC has recently pursued insider trading cases based on early access to clinical trial data or FDA communications. This MOU will make those cases easier to build. The agreement's timing also coincides with the rise of prediction markets for clinical trial outcomes, which creates new incentives for a wider range of people—including third-party statisticians, investigators, and lab personnel—to misuse confidential information. Companies should assume their FDA-related disclosures will be more readily verified by the SEC and should review their insider trading policies to ensure they adequately cover non-employee personnel with access to sensitive data.